Three-year results of application of nivolumab in patients with non-small cell lung cancer in clinical practice of the N.N. Blokhin Russian Cancer Research Center

Non-small cell lung cancer (NSCLC) is the leading cause of death from cancer worldwide. Despite the success over recent years in the treatment of NSCLC it has not yet been able to achieve good long-term survival. The development of immune checkpoint inhibitors has altered the landscape of treatment...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: K. K. Laktionov, K. A. Sarantseva, D. I. Yudin, V. V. Breder, E. V. Reutova, K. P. Laktionov
Materyal Türü: Artigo
Dil:Russo
Baskı/Yayın Bilgisi: Remedium Group LLC 2019-12-01
Seri Bilgileri:Медицинский совет
Konular:
immunotherapy
non-small cell lung cancer
checkpoint inhibitors
nivolumab
Online Erişim:https://www.med-sovet.pro/jour/article/view/5036
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller